Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 6—June 2014
Dispatch

Timeliness of Yellow Fever Surveillance, Central African Republic

Antoine Rachas1, Emmanuel Nakouné, Julie Bouscaillou, Juliette Paireau, Benjamin Selekon, Dominique Senekian, Arnaud Fontanet, and Mirdad KazanjiComments to Author 
Author affiliations: Institut Pasteur, Bangui, Central African Republic (A. Rachas, E. Nakouné, J. Bouscaillou, B. Selekon, M. Kazanji); Institut Pasteur, Paris, France (A. Rachas, J. Bouscaillou, J. Paireau, A, Fontanet); Ministry of Health, Bangui, (D. Senekian); Conservatoire National des Arts et Métiers, Paris (A. Fontanet)

Main Article

Table 2

Factors associated with timeliness of yellow fever surveillance, Central African Republic, 2007–2012*

Factor Mean timeliness, d Adjusted time ratio (95% CI) p value†
Age, y
<14 15.3 1.00 NA
15–24 16.5 1.13 (1.08–1.18) NA
25–34 16.8 1.15 (1.09–1.21) NA
≥35
18.6
1.21 (1.15–1.27)
<0.001
Sex
M 16.6 1.00 NA
F
16.5
1.01 (0.98–1.05)
0.43
Onset during rainy season
No 16.7 1.00 NA
Yes
16.5
1.01 (0.97–1.04)
NA
Province of residence
Bangui 14.8 1.00 NA
Ombella M’Poko 15.7 1.07 (1.02–1.12) NA
Lobaye 16.8 1.18 (1.09–1.28) NA
Sangha Mbaéré 17.6 1.17 (0.93–1.46) NA
Mambéré Kadéi 18.0 1.21 (1.03–1.41) NA
Nana Mambéré 20.7 1.43 (1.22–1.67) NA
Ouham Péndé 15.5 1.10 (1.01–1.19) NA
Ouham 17.0 1.19 (1.08–1.32) NA
Nana Grigbizi 22.9 1.56 (1.39–1.77) NA
Kemo 19.4 1.35 (1.21–1.51) NA
Bamingui Bangoran 17.5 1.24 (1.01–1.53) NA
Ouaka 19.2 1.34 (1.24–1.46) NA
Basse Kotto 16.5 1.19 (1.10–1.29) NA
Vakaga 20.1 1.38 (1.16–1.65) NA
Haute Kotto 17.4 1.25 (1.13–1.39) NA
Mbomou 26.2 1.86 (1.66–2.09) NA
Haut Mbomou
23.9
1.72 (1.37–2.15)
<0.001
Vaccination against yellow fever
Never 16.6 1.00 NA
>10 y ago 16.9 1.01 (0.93–1.09) NA
≤10 y ago 16.3 1.01 (0.96–1.05) NA
Unknown date
16.1
1.06 (0.92–1.23)
0.85
Year of onset
2007 17.8 1.00 NA
2008 17.3 1.02 (0.95–1.09) NA
2009 14.7 0.91 (0.85–0.98) NA
2010 16.8 1.04 (0.97–1.12) NA
2011 17.8 1.10 (1.02–1.18) NA
2012 16.6 1.05 (0.96–1.15) <0.001

*Adjusted time ratios are from a parametric survival model assuming log-normal distribution of the event times. A time ratio represents a relative increase in time between 2 groups. Timeliness was defined as the delay between the date of onset of jaundice (reported by the patient) and the date of ELISA result. NA, not applicable.
†By global Wald test.

Main Article

1Current affiliation: European Hospital Georges Pompidou and Descartes University, Paris, France.

Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external